Ozmosi | Etifoxine Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Etifoxine

Pronounced as: eh-tih-FOX-een

Alternative Names: etifoxine
Clinical Status: Active
Latest Update: 2025-05-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: BZD Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Algeria | Bulgaria | Chile | Colombia | France | Jordan | Lebanon | Malta | Morocco | Pakistan | Peru | Russia | South Africa | Tunisia | Ukraine | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Biocodex
Company Location: Europe
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Bipolar Disorder

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2021-006773-38

 2021-006773-38

P2

Active, not recruiting

Bipolar Disorder

2025-02-23

Recent News Events

Date

Type

Title

04/22/2024

PubMed

 The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.

02/06/2024

PubMed

 Exploring the Roles of Vitamins C and D and Etifoxine in Combination with Citalopram in Depression/Anxiety Model: A Focus on ICAM-1, SIRT1 and Nitric Oxide.

11/14/2023

PubMed

 Short-term effects of etifoxine on human gut microbiome in healthy men.

04/28/2023

News Article

 atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

03/06/2023

News Article

 atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

01/09/2023

News Article

 atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

10/20/2022

News Article

 atai Life Sciences Announces R&D Day Agenda

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions